FINWIRES · TerminalLIVE
FINWIRES

市場傳聞:索尼與本田合資企業擱置電動車計畫後,將探索其他合作機會以期實現合資目標

-- 根據《日經亞洲》週五報道,索尼(SONY)和本田汽車(HMC)的50/50合資企業在取消了此前共同開發電動汽車的計劃後,決定探索其他途徑來維持合資企業的運營。 報導稱,兩家公司正在討論非電動車產品和服務作為替代方案,並希望將他們的電動車技術應用於其他領域。 根據該媒體報道,索尼-本田移動出行公司仍有可能推出乘用車,但鑑於美國和中國汽車製造商在自動駕駛技術方面的進步,這將面臨挑戰。 索尼和本田尚未回覆的置評請求。 (市場動態新聞來自與全球市場專業人士的對話。這些資訊被認為是來自可靠來源,但可能包含傳聞和猜測。準確性無法保證。)

Price: $21.78, Change: $+0.31, Percent Change: +1.47%

Related Articles

Asia

Oneview Healthcare Reports Decline in Q1 Cash Receipts From Customers; Shares Up 3%

Oneview Healthcare (ASX:ONE) reported cash receipts from customers of about 3.3 million euros for the first quarter, compared with 4.2 million euros a year earlier, according to a Monday filing with the Australian bourse.The company noted that the year-ago figure includes two large customer receipts totaling more than 2 million euros, which were due to be received during the fourth quarter of 2024 but were received in early 2025.Oneview Healthcare ended March with a cash balance of AU$17.1 million, up from AU$8.1 million at the close of 2025, per the filing.The company's shares gained 3% in recent Monday trade.

$ASX:ONE
Asia

Paradigm to Advance Participants Through Day 112 Follow-Up Period in Phase Three Knee Osteoarthritis Trial, Shares Reach One-Year Low

Paradigm Biopharmaceuticals (ASX:PAR) is set to progress participants through the day 112 follow-up period for the phase three trial evaluating injectable pentosan polysulfate sodium for the treatment of pain associated with knee osteoarthritis in the June quarter, which is required for inclusion in the interim analysis dataset, according to a Monday Australian bourse filing.The independent statistical analysis results for the data set are expected around August. Timing remains subject to the scheduling and review processes of independent third parties, and there is a reasonable likelihood that final interim outcomes may extend into September, it cautioned.The interim analysis is expected to provide the first phase three evaluation of efficacy and safety for injectable pentosan polysulfate sodium in knee osteoarthritis. Primary endpoint top-line results are expected in the March 2027 quarter.Its shares fell 14% in recent trading on Monday, reaching their lowest point in over a year.

$ASX:PAR
Asia

Sanan Optoelectronics Q1 Profit Down 68%, Revenue Slides 33%

Sanan Optoelectronics (SHA:600703) posted first-quarter attributable net profit of 67.5 million yuan, down 68% from 211.9 million yuan the previous year.Earnings per share declined to 0.01 yuan from 0.04 yuan, according to a weekend filing with the Shanghai bourse.Operating revenue declined 33% year over year to 2.91 billion yuan from 4.31 billion yuan.Shares of the software company declined 2% in recent trade.

$SHA:600703